Pathologic complete response (pCR) after neoadjuvant chemotherapy has long been established as a biomarker associated with excellent prognosis.For those without pCR, prognosis correlates with residual cancer burden (RCB), 1 which stratifies the extent of residual cancer in breast and axilla into ascending categories of RCB I, II, and III, which in turn correlates with worse prognosis. 2Although RCB is an excellent prognostic marker, it does not take into account the possible impact of receptor profile change in residual disease.With recent advances in targeted therapies, especially HER2-directed therapies, 3,4 the frequency and clinical significance of receptor status change in residual disease is unclear.
No takes yet. Share an insight, caveat, or question.
Gottipati et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: